What makes a trial appealing for a patient?

Alastair Lamb

Cancer Research UK Clinician Scientist Fellow & Honorary Consultant Urologist, Oxford



11th Belgian Multidisciplinary Meeting on Urological Cancers

Brussels

bmuc.be/bmuc2024





CÔ		tps://ww	w. opcsg.org /home	page	Ē	80%	☆	\bigtriangledown	\mathbf{F}	111		٥	۴
ted	FX Foreign E	ស The	role of the prostati	🙂 YouTube - Ma	ary Popp	i 💜	Step 1 -	Who are y	ou?		3	» C] Oth
	OVE			TATE						f	You	Tube	

OXFORDSHIRE PROSTATE

About us Where to find help Get Checked Contact Partners Homenage Events

Oxfordshire Prostate Cancer Support Group has been providing support to those affected by prostate cancer since 2011. We provide friendship and support to patients, their partners and family,

We've traditionally used our initials, OPCSG as a short name, but are now in the process of rebranding to use OxMen, but are and will continue to be, the Oxfordshire Prostate Cancer Support Group.

We offer the opportunity to connect with others that have been in the same situation, to listen and share their own relevent experience of treatment and living with, and beyond, prostate cancer

If you or someone close to you has been affected by prostate cancer, we can offer:

- · One-to-one meetings with a member who has relevant experience;
- · Group meetings for everyone, both in-person and on-line;
- Separate private meetings for patients and partners to share worries and successes;
- · Social events, such as river cruises and skittles;
- · A newsletter with updates about upcoming events (hosted by OxMen and others);
- · Talks from experts, including representatives of:
 - The Urology Department at Oxford University Hospital Trust,
 - Prostate Cancer UK,
 - · Maggies,
 - Prostate Cancer Research.

· Clinical Trials and Studies

Our group meetings are safe spaces where we regularly discuss the physical and emotional impact of prostate cancer and treatment and share our personal experiences. We also offer one-to-one support and the opportunity to speak to people with experience of different treatments for those trying to make a decision; we do not offer medical advice, but will try to match you up with someone who can share their experience of a treatment you are interested in. This is open to everyone affected by prostate cancer, not just patients.

Email support@oxmen.org, or call 01865 595109, if you need support.

Partners can also contact us for dedicated support by emailing partners@oxmen.org directly.

Get Checked

If you are over 50 (younger for those with relevant family history and black men) you should talk to your GP about a prostate health check even if you have no symptoms. Catching prostate cancer early gives you a far better chance of beating it.

Symptoms and getting checked



Our Events

Everyone is welcome to come. They are informative and fun

We run regular awareness events, informative events and socials - where we get together in an easy environment to chat. Do come along.





Coming up

23 May 2022 - 7:00pm Clinical Research in Oxford and beyond

Richard Bryant and Alastair Lamb will provide an update on the TRANSLATE Tria

Venue: Oxford Golf Club and Online

See all events

Please click on each person to read their stories



Prance

Caroline Charlotte

Minett



Steve Tuck David Beeslev




Dafydd Charles









Jean Hawes









Will men with prostate cancer, or their relatives/partners etc., be involved in the design, planning or management of this research?

Yes

Please elaborate on their role (in no more than 500 words).

We have a close relationship with the Oxford Prostate Cancer Support Group (OPCSG; https://www.opcsg.org/homepage.), led by Mr Steve Tuck. We can provide evidence of collaboration from our recently NIHR-funded randomised controlled trial investigating techniques in prostate biopsy (the TRANSLATE Trial)(61) and our application to Cancer Research UK(62) for funding to support the QUANTUM Biobank with a prospective sample collection, also supported by OPCSG. We regularly present our research programme to OPCSG at one of their monthly Monday evening meetings at which we are regular speakers, and likewise present our findings to update them on progress. Although we do not plan to include a PPI member as a co-applicant on this award, we believe that we already have the required PPI support for QUANTUM, this being the medium through which patients who contribute samples to this study will be recruited. Steve Tuck is a member of our Tissue Access Committee for QUANTUM and has kindly reviewed and provided feedback on the lay components of this PCUK Research Innovation Award application.



Fourth floor Telephone 020 3310 7000 The Counting House 53 Tooley Street info@prostatecanceruk.org prostatecanceruk.org



Tweet



Alastair Lamb @LambAlastair

Really enjoyed our evening with #OPCSG Oxford Prostate Cancer Support Group @oxford_golfclub (1st time back in person!) updating on #TRANSLATE_Trial & @LabBryant's plans for future #TopNotchScience in #ProstateCancer.

Great crowd. Great questns. Thanks @SteveTuck for having us



5:38 PM · Sep 15, 2021

III View Tweet analytics

Promote

...



#Oxford_Urology



Steve Tuck and 9 others

Tweet



Alastair Lamb @LambAlastair

Really enjoyed our evening with #OPCSG Oxford Prostate Cancer Support Group @oxford_golfclub (1st time back in person!) updating on #TRANSLATE_Trial & @LabBryant's plans for future #TopNotchScience in **#ProstateCancer.**

Great crowd. Great questns. Thanks @SteveTuck for having us



5:38 PM · Sep 15, 2021

III View Tweet analytics

3 Retweets

16 Likes

Promote

...



Alastair Lamb @LambAlastair · May 28, 2022 @mercaderclaudia talks to Oxford Prostate Cancer Support Group **#OPCSG** about "Why come from Barca to Oxford to do a fellowship?" 5 lessons learned: not only 1 way to do things ask why involve ur pts ·learn from ur results •England is more than just London!

#Oxford Urology



@CELovegrove

Well, this is encouraging! #OPCSG #Waterworks #PCa #prostatecancer #OxfordUrology @OUHospitals @NDSurgicalSci 🚰 opcsg.org



5:05 PM · Jul 7, 2019

NIHR | National Institute for Health Research

NIHR Health Technology Assessment Programme

Page 15 of 40

PATIENT & PUBLIC INVOLVEMENT

Please describe how patient and the public have been involved in developing this proposal

Patients and the public have been actively involved in the conception and development of this proposal. A preliminary meeting was organised by the Oxford Prostate Cancer Support Group on 14/10/19 where Alastair Lamb (Co-Lead Investigator) introduced the trial concept and asked for feedback. The meeting was attended by 52 people including previous prostate cancer patients, their partners and friends. They were asked to consider four questions:

1. What most concerns / concerned you about having a prostate biopsy?

 Would men accept randomisation between the two forms of biopsy (given that the current standard of care is transrectal biopsy)?

- 3. What most embarrassed you/would most embarrass you about having a biopsy?
- 4. How best to record outcomes after a biopsy?

The trial team discussed the answers to these questions after this first meeting to inform the content of the first stage application. There was general agreement that there is lack of evidence with regards to the approach to diagnostic prostate biopsy, and that patients and their families agreed that the TRANSLATE Trial is very worthwhile and likely to improve patient management and should proceed. As a result of this meeting first meeting, Mr Steve Tuck (OPCSG chair and previous prostate cancer patient) volunteered to be a co-applicant on this application, and to act as patient advocate for the trial. The OPCSG agreed to support the TRANSLATE trial, and to perform an anonymous survey prior to submission of stage 2 of the application, and to publicise the trial and its findings within their, and other, related groups, and on their website and in their newsletter.

After several meetings of the trial management group with Mr Steve Tuck, a confidential survey was undertaken between 26th March to 30th April 2020 by OPCSG amongst its members, and amongst other patient members of NCRI Prostate, and Thames Water – the latter being important to include a sample of men who had not already undergone a prostate biopsy. Eight questions were included, covering the above items and anonymous demographic data. There were 72 respondents, 60% of whom had not previously undergone prostate biopsy. Of these 58 (80%) were 'very likely' or Tikely' to accept randomisation, and 70% would be 'very willing' or 'willing' to be randomised on the day of the procedure. The vast majority rated 'diagnosis of cancer' as the primary concern in undergoing a biopsy, with 'avoiding infection (sepsis)' a close second concern. The need to avoid repeat biopsy was 'very important' or 'important' for 80% of men, and it was interesting to note that surprisingly few men (15%) were concerned about loss of erectile function. The survey also highlighted the concern to avoid pain/discomfort, and to maintain personal dignity.

The trial management group believe that the results of this survey conducted by OPCSG underline the importance of investigating detection of clinically significant prostate cancer as the primary outcome, with infection rates and patient perception of the biopsy as important secondary outcomes. In light of the feedback regarding perception of discomfort and personal dignity, we have amended the patient reported outcome measures (PROMs) to include assessment immediately after the procedure, as well as at 7 days, in order to minimise the possibility of 'recall bias' or 'context bias' in the event of a pleasing outcome from the biopsy (i.e. avoidance of a prostate cancer diagnosis).

Please describe the ways in which patients and the public will be actively involved in the proposed research, including any training and support provided

Patients and the public will continue to be actively involved throughout the trial. Mr Steve Tuck, as a co-applicant, will attend regular trial management group meetings. We will continue to update the Oxfordshire Prostate Cancer Support Group (OPCSG) and the National Cancer Research Institute (NCRI) patient advocates about the progress of the trial.

If funding is awarded, members of the OPCSG will be involved in the design and final approval of the patient information sheet, the family information sheet and the consent form for the TRANSLATE trial. Their involvement is vital to help make the language and information content of these documents

IR 131233 sociate Professor Richard John Bryant - The Chancellor Masters and Scholars of the University of Oxford vised Stage 2 Application GDPR - Applicant NIHR Health Technology Assessment Programme

Please describe the ways in which patients and the public will be actively involved in the proposed research, including any training and support provided

understandable to patients and families at a period of great stress, and to make them relevant to recruitment centres across the UK.

We outline below the ways in which our PPI colleagues will continue to be involved through the trial: 1. Research design: Mr Steve Tuck will continue to be involved in regular Trial Management Group meetings to finalise the trial design.


 Research Management: Individuals who agree to contribute to the management of the project will meet the Clinical Trials Unit (CTU) individually, to gain understanding of their previous involvement in clinical trials (if any). Appropriate training will be offered and participation will be tailored appropriately. The induction pack for PPI contributors on Trial Oversight Committees is invaluable, preliminary reading.

3. Participant information resources development: A short video for potential participants describing the trial will be available on the CTU website. The lead applicants will explain the background and rationale for the trial, and what participation would entail. Patient/carer feedback for this will be vital, for which we will engage OPCSG. Furthermore, a number of patients have expressed a desire for involvement in the writing of the patient information sheet, and relevant details for inclusion on the trial website. In addition, with appropriate permission, short videos will be made available of trial participants, providing their real life experience of inclusion (e.g. the questions asked, assessments undertake, etc).

4. Contribution to research reporting: As a NIHR funded project, the standard monograph will be produced, however we will be working with our PPI collaborators to ensure any plain English parts of the monograph are phrased appropriately to ensure that the findings can be interpreted correctly by all audiences, and we would hope to produce an infographic if possible, to explain the findings.

5. Dissemination of research findings: With our patient co-applicant, and PPI groups mentioned above, communication for patients/carers and the public will be developed. Newsletters, Facebook, Twitter etc. will be used to ensure the results of TRANSLATE are communicated to the wider community once they are available. In addition, the TRANSLATE team will follow the Public Involvement Impact Assessment Framework to maximise PPI in the trial.

In rare cases where proposals do NOT involve patients and the public, clear justification must be provided N/A









CONTENT	DETAILS OF TMG					
4. Composition						
Membership and size of the TMG	The members of the TMG for this trial are:					
	 (1) Associate Professor Richard John Bryant - Chief Investigator 					
	(2) Mr Alastair D Lamb - Co-Chief Investigator					
	(3) Roxanne Williams – Trial Manager					
	(4) Nadjat Medeghri - SITU Operational Lead					
	(5) Lucy Davies - Clinical Trials Development Lead					
	(6) Ioana Marian- Trial Statistician					
	(7) Aimi Hewitt – Data Manager					
	(8) Filipa Landeiro – Senior researcher in health economics					
	(9) Jane Wolstenholme - Associate Professor of Health Economics					
	(10) Francisco Lopez - Pelvic Uro-Oncology Fellow					
	(11) Teresa Campbell - Urology Advanced Nurse Practitioner					
	(12) Clare Verrill - Consultant Pathologist					
	(13) Ruth MacPherson - Consultant Radiologist					
	(14) Jane Holmes – Senior Statistician					
	(15) Steve Tuck - PPI					
	Members of the TMG should disclose potential competing interests (see Section 5).					
The Chair, how they are chosen and the Chair's role (Likewise, if	The Chair of the TMG will be the Chief Investigator: Richard John Bryant.					
relevant, the vice-Chairman)	The CI will be a member of the TSC and must attend all TSC meetings. The CI should be available to attend DSMC meetings. The other TMG members will not usually be expected to routinely attend TSC or DSMC meetings but may attend sessions when necessary and appropriate.					
The responsibilities of the trials unit team	The trials unit team (e.g. Trial Manager, etc) will be responsible for running the trial on a day-to-day basis, maintaining trial databases, randomising patients, ensuring complete and correct data, preparing short reports for meetings (including those of the TMG) and dealing with research governance and, if appropriate, regulatory matters.					

NICE National Institute for Health and Care Excellence



Transperineal biopsy for diagnosing prostate cancer

Diagnostics guidance Published: 1 June 2023

www.nice.org.uk/guidance/dg54

Recommendations

- 1.1 Local anaesthetic transperineal (LATP) prostate biopsy using the freehand needle positioning device PrecisionPoint is recommended as an option for diagnosing prostate cancer.
- 1.2 Although there is considerably less evidence and therefore greater uncertainty of clinical benefit for them, the following freehand needle positioning devices are expected to have similar cancer detection rates and adverse events to those of PrecisionPoint:
 - EZU-PA3U device
 - Trinity Perine Grid
 - UA1232 puncture attachment.

There are technical differences between them, but they all work in a similar way using the same biopsy technique. So, these devices are recommended as options for diagnosing prostate cancer.

- 1.3 Centres are encouraged to take part in research and data collection, including the randomised controlled trial of transrectal biopsy compared with LATP biopsy (the TRANSLATE trial; see <u>section 3.8</u>) to help refine clinical practice.
- 1.4 There is not enough evidence to recommend double freehand LATP prostate biopsy using the CamPROBE device. Further research is recommended to understand its clinical effectiveness.

Why the committee made these recommendations

Standard prostate biopsy uses local anaesthetic transrectal ultrasound (LA-TRUS). This involves taking samples of prostate tissue by inserting a biopsy needle through the rectal wall via the anus. An alternative is LATP prostate biopsy, which involves inserting the needle through the perineum, the skin area between the anus and the scrotum.

Techniques for LATP biopsy vary. It can be done using a freehand needle positioning

© NICE 2023. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-andconditions#notice-of-rights). 23 Clinical experts explained that there is a move towards using LATP nationally and that some centres no longer do TRUS prostate biopsies.

Participation in the ongoing TRANSLATE RCT is encouraged to generate further evidence to help refine clinical practice

3.8 The ongoing TRANSLATE RCT will provide further comparative evidence on LA-TRUS biopsy and LATP biopsy using a freehand needle positioning device. The trial aims to recruit 1,042 people with a prostate over 15 months from 9 NHS hospitals in the UK. The protocol says that an average of around 12 systematic biopsy cores will be taken, depending on prostate size, with an additional 4 target biopsy cores for each significant lesion seen on prebiopsy MRI. The primary outcome is detection rates of clinically significant prostate cancer. Secondary outcomes include rates of infection, health-related quality of life, patientreported tolerability of the procedure, patient-reported biopsy-related complications, number of subsequent prostate biopsy procedures, cost effectiveness, and histological parameters. The trial will last for 31 months and is expected to end in October 2023. The committee concluded that centres should be encouraged to participate in research and data collection, including the TRANSLATE RCT, to generate more evidence to help understand the effects of differences between the LATP and LA-TRUS biopsy approaches and refine clinical practice.

Cost effectiveness

The committee prefers the new assumptions used in the EAG's revised analysis

- The committee considered the original and revised base-case analyses 3.9 and noted that in the revised analysis, the key differences with the largest effect on the incremental cost-effectiveness ratios (ICERs) were that:
 - studies that used spinal anaesthesia were excluded

Transperineal biopsy for diagnosing prostate cancer (DG54)

Diagnostics advisory committee 6 members and NICE project team

Committee members

This topic was considered by the diagnostics advisory committee, which is a standing advisory committee of NICE.

Committee members are asked to declare any interests in the tests to be assessed. If it is considered there is a conflict of interest, the member is excluded from participating further in that assessment.

The minutes of each committee meeting, which include the names of the members who attended and their declarations of interests, are posted on the NICE website.

Additional specialist committee members took part in the discussions for this topic:

Specialist committee members

Hashim Ahmed Professor of urology, Imperial College Healthcare NHS Trust

Tristan Barrett Consultant radiologist, Addenbrooke's Hospital, Cambridge

Sanieev Madaan Consultant urological surgeon and lead cancer clinician, Darent Valley Hospital, Dartford

Jon Oxley Consultant in cellular pathology, North Bristol NHS Trust

Michele Pietrasik Prostate cancer clinical nurse specialist, Royal Surrey County Hospital NHS Foundation Trust

Transperineal biopsy for diagnosing prostate cancer (DG54)

Graeme Spencer Lay specialist

Santhanam Sundar Consultant oncologist, Nottingham University Hospitals NHS Trust

David Wakefield Lay specialist

Clinical expert

Hide Yamamoto Consultant urologist, Maidstone and Tunbridge Wells NHS Trust

NICE project team

Each diagnostics assessment is assigned to a team consisting of a technical analyst (who acts as the topic lead), a technical adviser and a project manager.

Simon Webster Topic lead

Frances Nixon Technical adviser

Donna Barnes Project manager (February 2021 to April 2022)

Toni Gasse Project manager (May 2022 to June 2023)

ISBN: 978-1-4731-5199-4

In NICE 2023. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-Page 15 of conditions#notice-of-rights).

23








Clinical Trial Participation Survey

This survey aims to understand what factors make clinical trials appealing to potential participants.





11th Belgian Multidisciplinary Meeting on Urological Cancers





https://www.opinionstage.com/page/234f226d-462b-4891-926e-20ee92d4c907



Please tell us a little about you:



	Answer		Votes			
	20-30s		12.0% / 18			
	40-50s		14.7% / 22			
	60-70s		30.0% / 45			
	80-90s		6.7% / 10			
	Former patie	ent	18.7% / 28			
	Current pati	ent	13.3% / 20			
	Possible fut	ure patient	4.7% / 7			
Views ⑦		Started 💿		Completed ⑦	Average Time ⑦	
● 182		ඛී 71% (13	30)	Ø 77% (100)	⊘ 4:44	



What could be your main reasons for considering participation in a clinical trial? (up to 3 options)



Answer	Votes	
Access to new treatments	23.6% / 65	
Financial compensation	<mark>3.6</mark> % / 10	9.1% 23.6%
Contributing to medical research	28.3% / 78	5.1%
Recommendation from your consultant or nurse	5.4% / 15	3.6%
Helping future patients	21.4% / 59	21.4%
Opportunity to engage in interesting science	9.1% / 25	28.3%
Expectation of more personalised care than normally get in NHS / health service	8.0% / 22	
Other	0.7% / 2	



How important is the possibility of health benefits when deciding to participate?




Answer	Votes	
Very important	49.0% / 49	4%
Somewhat important	34.0% / 34	
Neutral	11.0% / 11	49%
Not very important	4.0% / 4	
Not important at all	2.0% / 2	34%
Total votes 100		



What level of risk are you willing to accept in a clinical trial?






How many extra visits would you be willing to undertake to participate in a clinical trial?



Answer	Votes				
As many as required	52.0% / 52				
1 visit per week	19.0% / 19				
1 visit per month	29.0% / 29				
1 visit per year	0.0% / 0				
No visits at all	0.0% / 0				
Total votes 100					









What type of support services would make a clinical trial appealing to you?











In your own words, what would be the ideal experience for you as a participant in a clinical trial?

	• •	•					II Deigian Multidiscipiniary
Answers Report	Answer	2024-03-15 11:22:35	A successful outcome, be it to prove or disprove a medical treatment	2024-03-15 00:48:30	I assume that I have benefitted from the research done before and therefore if anything can be learned from the treatment I have received I shall feel that I		Meeting on Urological Cancers To feel I have been personally responsible in some small way to further the advance of research in finding solutions that
2024-03-15 18:53:27	Improvement in condition.	2024-03-15 10:44:09	Personalised care that enhances the standard level of treatment		have reciprocated. Thank you. A confortable area for the tour Clear and concise explanation of the trail and	2024-03-15 05:58	benefit patients and make their lives better. If I have personally benefited healthwise, that is a bonus.
2024-03-15 14:48:21	To be treated as an individual rather than being one of many on a treatment	2024-03-15 10:10:26	Good communication and knowing what to expect.	2024-03-15 08:00:20	possibility of side effects. Transportation assistance (I don't drive) To be able to help new patients and put	2024-03-15 05:48	Understanding of trial purpose, length, value of A good rapport with clinicians,staff Information of result
	conveyer belt To feel that my input really can make a		Good <u>clear communication</u> with reduce medical terminology such that I can have	2024-03-15 07:57:41	back something to recognise the support I received .		Assessment of potential risks before accepting and ability to pull out if becoming very unwell
2024-03-15 14:45:58	difference. To know that my opinion matters.	2024-03-15 10:10:23	a good level of understanding throughout the process. Additionally, follow up	2024-03-15 07:31:18	A process that made kept me informed about and as far as possible helped me	2024-03-15 05:44	Worthwhile trial, good organisation, regular communication, genuine
2024-03-15 14:08:30	Clear understanding of the objective/ purpose of the trial. A low level of risk and		bulletins on the outcomes of the trial where applicable.		feel involved in the trial.		appreciation, information on milestones and outcome.
2024-05-15 14:08:50	impact on quality of life. Clear outcomes that l can support and champion.	2024-03-15 10:03:51	A successful outcome but good clinical care	2024-03-15 07:27:29	the clinicians and those managing the trial would make the experience feel worthwhile and rewarding for me.	2024-03-15 05:40	If it took about an hour or two and at a time convenient to me
2024-03-15 13:15:39	Full information about objectives and results	2024-03-15 09:30:35	Kept well informed through the process	2024-03-15 07:26:46	Good personal interaction, being kept informed, not too long.	2024-03-15 05:39	For there to be a good outcome
2024-03-15 12:33:17	That I would be getting some health benefit, or knowing it will help someone close to me.	2024-03-15 09:29:24	To contribute to the advancement of an improved success rate		Sharing experiences with others in similar situations, and at different stages of the journey. Understanding the benefits and	2024-03-15 05:34	Knowing that you had made a contribution, however small, to medical science.
2024-03-15 12:30:35	One whereby you have personal health feedback		' Time to review the information prior to consent, delays in treatment/prescription	2024-03-15 07:21:09	being able to contribute to the trial objectives. Observing or even experiencing the benefits. Seeing a trial	2024-03-15 05:27	Be offered financial compensation and be kept up to date with the details of the trai all the way to the papers publication.
2024-03-15 12:07:39	To be able to help scientific advancement with as little science my braith as is	2024-03-15 09:22:03	minimsed where possible depending on		gaining its rightful place in the treatment toolbox.		Being involved and informed (even if after the fact) about the outcome of the trial,
(possible and relatively little income sience I'd like to discuss the science involved,		options would be available to me off a clinitar trial.	2024-03-15 07:01:21	In an area where I have concerns for myself or my grandchildren	2024-03-15 05:21	and thanked for my contribution to it (even if in a control group).
2024-03-15 11:49 0	and be told about the eventual trial outcome.	2024-03-15 09:01:17	Being explained as much as possible what the trial is for and the possible future benefits	2024-03-15 06:55:40	Information about the trial	2024-03-15 05:19	A better outcome than traditional treatment.
2024-03-15 11:24:58	Ownershere I get to asses my character health for a specific I topic like PCOS and this directly impact the approval of a new good treatment to improve woman's health.	2024-03-15 09:00:40	Probably just go with the flow!	2024-03-15 06:48:31	Knowing that my participation would contribute to better diagnosis / treatment / outcomes for patients in the future, plus		To be kept up to date before, throughout and after the trial. To be communicated with empathy, understanding and kindness. To be regarded as a person and
		2024 02 15 09:54:24	Participating would be important to me for a hopefully positive outcome as well as progressing the treatment for other		possibly giving me access to treatment not yet widely available.	2024-03-15 05:17	not just a patient. I believe it's important for consultants and medical professionals to get to know their patients as people in
F9		2024-03-15 08:51:24	for a hopefully positive outcome as well		possibly giving me access to treatment	2024-03-15 05:17	not just a patient. I belie for consultants and mee











11th Belgian Multidisciplinary Meeting on Urological Cancers

SILVER SPONSORS



BRONZE SPONSORS





PLATINUM CORPORATE SPONSORS **GOLD SPONSORS** Astellas Johnson&Johnson AstraZeneca ONCOLOGY MSD Marketing Authorisation Holder **Pfizer CORPORATE SPONSORS** BAYER accord FIPSEN Innovation for patient care We make it better Histol Myers Squibb **U**NOVARTIS